

3050 Spruce Street, St. Louis, MO 63103 USA
Tel: (800) 521-8956 (314) 771-5765 Fax: (800) 325-5052 (314) 771-5757
email: techservice@sial.com sigma-aldrich.com

# **Product Information**

#### Anti-Twist1

produced in rabbit, affinity isolated antibody

Catalog Number T6451

## **Product Description**

Anti-Twist1 is produced in rabbit using a synthetic peptide corresponding to amino acids 12-27 of human Twist1 with a C-terminal added cysteine, conjugated to KLH, as immunogen. The corresponding peptide sequence is identical in both rat and mouse. The antibody is affinity-purified using the immunizing peptide immobilized on agarose.

Anti-Twist1 recognizes human Twist1 by immunoblotting (~26 kDa) and immunofluorescence. Detection of the Twist1 band by immunoblotting is specifically inhibited with the immunizing peptide. Minor additional bands may be detected in some extract preparations.

The basic helix-loop-helix (bHLH) transcription factor Twist, first discovered in *Drosophila*, was found to be essential in mesoderm formation. Two Twist-like proteins were found in mammals, Twist and Dermo1, also known as Twist1 and Twist2, respectively. Twist1 was found to be required in head mesenchyme for cranial neural tube morphogenesis in mice. Twist1 is involved in osteoblast differentiation and maturation. It represses expression of proinflammatory cytokines such as TNF $\alpha$  and IL-1 $\beta$  and interacts with the histone acetyltransferase domains of p300 and PCAF inhibiting their acetyltransferase activities. Mutations in this gene have been found in patients with Saethre-Chotzen syndrome, an autosomal dominant defect characterized by minor skull and limb anomalies.

Twist1 is a regulator of embryonic morphogenesis and plays an essential role in metastasis by promoting an epithelial-mesenchymal transition (EMT). During an EMT, Twist induces the expression of mesenchymal markers, such as fibronectin and N-cadherin, and represses E-cadherin expression inhibiting cell-cell adhesion and therefore inducing infiltrative tumor growth in various human carcinomas. Twist over-expression in breast cancer cells can induce angiogenesis and correlates with chromosomal instability.

# Reagent

Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Antibody concentration: ~1 mg/mL

#### **Precautions and Disclaimer**

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

### Storage/Stability

For continuous use, store at 2-8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in "frost-free" freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.

#### **Product Profile**

 $\underline{Immunoblotting} \hbox{: a working antibody concentration of } \\ 0.5-1~\mu g/mL \hbox{ is recommended using extracts of human } \\ 293T \hbox{ cells expressing recombinant human Twist1 and a chemiluminescent detection reagent.} \\$ 

**Note**: The molecular weight band (~26 kDa) was observed with a myc-tagged protein.

Indirect immunofluorescence: a working antibody concentration of 1-2  $\mu$ g/mL is recommended using osteosarcoma MG-63 cells.

**Note**: In order to obtain the best results using various techniques and preparations, we recommend determining the optimal working dilutions by titration.

#### References

- Thisse, B., et al., Nucleic Acids Res., 15, 3439-3453 (1987).
- Bourgeois, P., et al., Mamm. Genome, 7, 915-917 (1996).
- 3. Sosic, D., et al., Cell, 112, 169-180 (2003).

- 4. Chen, Z.F. and Behringer, R.R., *Genes Dev.*, **9**, 686-699 (1995).
- 5. Bialek, P., et al., Develop. Cell, 6, 423-435 (2004).
- 6. Hamamori, Y., et al., Cell, 96, 405-413 (1999).
- 7. Howard, T.D., et al., Nat. Genet., 15, 36-41 (1997).
- 8. Yang, J., et al., Cell, 117, 927-939 (2004).
- 9. Mironchik, Y., et al., *Cancer Res.*, **65**, 10801-10809 (2005).

ST,KAA,PHC 04/09-1